Successful treatment of refractory cold agglutinin syndrome using fixed duration daratumumab, bortezomib and dexamethasone with a sutimlimab bridge., PMID:40400475
Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab., PMID:39503157
Autoimmune haemolytic anaemias., PMID:39487134
Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease., PMID:39402301
Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy., PMID:39371250
[New drugs for the treatment of primary immune thrombocytopenia]., PMID:39358266
Sutimlimab for Cold Agglutinin Disease., PMID:39328891
Adult-onset severe paroxysmal cold hemoglobinuria after COVID-19 successfully treated with sutimlimab., PMID:39304597
[The treatment strategies of autoimmune hemolytic anemia]., PMID:39134500
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension., PMID:39114274
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B., PMID:39091672
Efficacy of sutimlimab for cold agglutinin disease in a patient on chronic hemodialysis., PMID:39017802
Diagnosis and management of Evans syndrome in adults: first consensus recommendations., PMID:38968944
[Cold agglutinin disease: pathology, diagnosis, and treatment]., PMID:38960651
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease., PMID:38872338
Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897., PMID:38809539
Cost-effectiveness of sutimlimab in cold agglutinin disease., PMID:38733355
[Sutimlimab for cold agglutinin disease, a newcomer among complement inhibitors in immunohematology]., PMID:38719668
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study., PMID:38519606
COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab., PMID:38385639
Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease., PMID:38148014
Antibody based therapeutics for autoimmune hemolytic anemia., PMID:37874225
Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps., PMID:37795092
[Novel therapeutic agents for hemolytic anemia]., PMID:37793862
Novel therapeutics and future directions for refractory immune thrombocytopenia., PMID:37735554
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up., PMID:37459203
[Novel anti-complement therapeutics for hemolytic anemia]., PMID:37407469
Molecular pharmacology in complement-mediated hemolytic disorders., PMID:37308291
Complement-directed therapy for cold agglutinin disease: sutimlimab., PMID:37256550
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease., PMID:37246953
Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease., PMID:37164370
Sutimlimab for the Treatment of Cold Agglutinin Disease., PMID:37153870
Monoclonal antibodies for treatment of cold agglutinin disease., PMID:37128907
Rise of the planet of rare anemias: An update on emerging treatment strategies., PMID:36698833
Recent progress in ITP treatment., PMID:36622549
Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis., PMID:36476151
Antibodies to watch in 2023., PMID:36472472
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study., PMID:36403132
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease., PMID:36322823
Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?, PMID:36127205
A virtuosic CADENZA played by sutimlimab., PMID:36048476
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study., PMID:35999387
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia., PMID:35973190
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?, PMID:35946351
Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia., PMID:35747120
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial., PMID:35687757
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial., PMID:35655238
Sutimlimab: First Approval., PMID:35412113
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia., PMID:35282954